Verastem(VSTM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VSTM Verastem

盘前交易 11-06 08:09:48 EST

9.38

-0.47

-4.77%

盘前8.75

-0.63-6.73%

08:09 EST

最高9.86	最低9.16	成交量304.84万
今开9.86	昨收9.85	日振幅7.11%
总市值11.35亿	流通市值10.04亿	总股本1.21亿
成交额2,885万	换手率2.85%	流通股本1.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VSTM","market":"US","secType":"STK","nameCN":"Verastem","latestPrice":9.38,"timestamp":1793912400000,"preClose":9.85,"halted":0,"volume":3048442,"hourTrading":{"tag":"盘前","latestPrice":8.7489,"preClose":9.38,"latestTime":"08:09 EST","volume":10460,"amount":90687.39458000001,"timestamp":1793970568143,"change":-0.6311,"changeRate":-0.067281,"amplitude":0.03838},"delay":0,"changeRate":-0.047715736040609025,"floatShares":107000000,"shares":121000000,"eps":-2.414264,"marketStatus":"盘前交易","change":-0.47,"latestTime":"11-06 08:09:48 EST","open":9.86,"high":9.86,"low":9.16,"amount":28848565.05396,"amplitude":0.071066,"askPrice":8.9,"askSize":500,"bidPrice":8.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.414264,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793975400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1327640400000,"exchange":"NASDAQ","adjPreClose":9.38,"preHourTrading":{"tag":"盘前","latestPrice":8.7489,"preClose":9.38,"latestTime":"08:09 EST","volume":10460,"amount":90687.39458000001,"timestamp":1793970568143,"change":-0.6311,"changeRate":-0.067281,"amplitude":0.03838},"postHourTrading":{"tag":"盘后","latestPrice":8.81,"preClose":9.38,"latestTime":"19:45 EST","volume":104569,"amount":939488.9609,"timestamp":1793925955819,"change":-0.57,"changeRate":-0.060768,"amplitude":0.115139},"volumeRatio":1.2999668403390297,"impliedVol":1.0238,"impliedVolPercentile":0.324},"requestUrl":"/m/hq/s/VSTM","defaultTab":"news","newsList":[{"id":"1175058550","title":"财报前瞻 | Verastem本季度营收预计增360.80%，机构观点看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1175058550","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175058550?lang=zh_cn&edition=full","pubTime":"2026-10-29 15:33","pubTimestamp":1793259219,"startTime":"0","endTime":"0","summary":"Verastem将于2026年11月05日发布最新季度财报，市场聚焦商业化收入质量与管线催化进展。市场一致预期本季度Verastem营收为2,607.84万美元，同比增360.80%；调整后每股收益为-0.46美元，同比改善27.80%；公司与市场未提供本季度毛利率、净利率或净利润的预测数据。综合多家机构的结论，本季度市场更关注收入质量与费用结构的匹配、以及VS-7375的后续数据发布节点；若营收实现一致预期的2,607.84万美元并且每股亏损按预期同比改善27.80%，机构看多的核心逻辑将获得阶段性验证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Verastem本季度营收预计增360.80%，机构观点看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675873340","title":"Verastem触发波动性停牌，股价上涨5.6%，此前跌幅已被抹平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2675873340","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675873340?lang=zh_cn&edition=full","pubTime":"2026-10-14 21:44","pubTimestamp":1791985448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675480963","title":"Verastem股价盘前上涨22.9%，消息面上，公司任命Michael P. Bailey为总裁兼首席执行官。","url":"https://stock-news.laohu8.com/highlight/detail?id=2675480963","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675480963?lang=zh_cn&edition=full","pubTime":"2026-10-14 18:16","pubTimestamp":1791972976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129499733","title":"Verastem Oncology 公布2026年第二季度财务业绩 并强调近期业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1129499733","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129499733?lang=zh_cn&edition=full","pubTime":"2026-08-07 04:05","pubTimestamp":1786046752,"startTime":"0","endTime":"0","summary":"Verastem Oncology 发布了2026年第二季度的财务报告。与此同时，该公司还重点介绍了近期取得的业务进展。这些成果与更新，为市场观察其发展态势提供了关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161579487","title":"Verastem Oncology启动VS-7375口服Kras G12d抑制剂针对Kras G12d突变转移性结直肠癌的Target-D 203 II期注册导向试验，首位患者已接受给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1161579487","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161579487?lang=zh_cn&edition=full","pubTime":"2026-07-29 04:02","pubTimestamp":1785268932,"startTime":"0","endTime":"0","summary":"Verastem Oncology今日宣布，其针对Kras G12d突变转移性结直肠癌的Target-D 203 II期注册导向试验已实现关键里程碑——首位患者成功接受给药。该试验旨在评估VS-7375这款口服Kras G12d（on/off）抑制剂的疗效与安全性。VS-7375是一种靶向Kras G12d突变蛋白的小分子药物，通过同时抑制其激活和失活状态，有望为这一特定基因突变类型的晚期结直肠癌患者带来新的治疗选择。此次试验的启动标志着Verastem在精准肿瘤学领域迈出重要一步，为后续注册申请积累关键临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193738521","title":"Verastem启动VS-7375针对KRAS G12D突变晚期非小细胞肺癌的TARGET-D 202 II期注册导向试验首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1193738521","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193738521?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:02","pubTimestamp":1784750534,"startTime":"0","endTime":"0","summary":"Verastem Oncology已为其针对KRAS G12D突变晚期非小细胞肺癌的在研药物VS-7375，启动了TARGET-D 202 II期注册导向试验，并完成了首例患者的给药。这项试验旨在评估该疗法的疗效与安全性，目标是为后续的注册申请提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171317225","title":"VS-7375在晚期KRAS G12D突变实体瘤患者的Target-D 101 I/II期临床试验中展现临床活性，安全性与耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1171317225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171317225?lang=zh_cn&edition=full","pubTime":"2026-06-24 04:02","pubTimestamp":1782244952,"startTime":"0","endTime":"0","summary":"在针对晚期KRAS G12D突变实体瘤患者开展的Target-D 101 I/II期临床试验中，候选药物VS-7375显示出积极的临床活性信号，同时其安全性与耐受性特征表现良好。该试验结果初步验证了该药物在这一难治性患者群体中的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187616620","title":"Verastem公布RAMP 205研究积极更新数据：Avutometinib联合Defactinib及标准化疗一线治疗转移性胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1187616620","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187616620?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:31","pubTimestamp":1781695879,"startTime":"0","endTime":"0","summary":"Verastem Oncology近日公布了RAMP 205研究的积极更新结果。该研究旨在评估Avutometinib联合Defactinib，并与标准护理化疗方案相结合，用于一线治疗转移性胰腺癌患者的疗效与安全性。\n最新数据显示，这一联合疗法展现出令人鼓舞的临床活性。研究结果进一步支持了该组合疗法在应对这一难治性癌症方面的潜在价值。胰腺癌治疗领域长期面临挑战，此次更新为患者带来了新的希望。\n公司将继续推进相关临床开发计划，深入探索该联合疗法在更大患者群体中的表现。这些积极进展也为后续的临床策略与潜在监管申请奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130135230","title":"Verastem Oncology启动VS-7375治疗Kras G12d突变胰腺癌II期注册试验，首位患者已用药","url":"https://stock-news.laohu8.com/highlight/detail?id=1130135230","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130135230?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:02","pubTimestamp":1781640137,"startTime":"0","endTime":"0","summary":"Verastem Oncology宣布，其针对Kras G12d突变转移性胰腺癌的口服抑制剂VS-7375，已在名为Target-D 201的II期注册导向试验中，为第一位患者完成给药。这项关键性研究旨在评估该药物的疗效与安全性，标志着该创新疗法向潜在注册上市迈出了实质性一步。VS-7375是一种新型的Kras G12d（开/关）抑制剂，其设计旨在精准靶向这一在胰腺癌中常见的特定基因突变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131158197","title":"Verastem Oncology宣布口服潜在同类最佳在研药物VS-7375获美国FDA快速通道认定，用于治疗KRAS G12D突变局部晚期或转移性非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1131158197","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131158197?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:02","pubTimestamp":1780516936,"startTime":"0","endTime":"0","summary":"Verastem Oncology宣布，其口服、潜在同类最佳在研KRAS G12D（开/关）抑制剂VS-7375，已获得美国食品药品监督管理局（FDA）的快速通道认定。该药物旨在用于治疗携带KRAS G12D突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者。\n快速通道认定旨在加速针对严重疾病且能填补未满足医疗需求的药物的开发和审评进程。这一认定意味着VS-7375有潜力解决KRAS G12D突变NSCLC这一关键临床需求领域。对于Verastem而言，这是其管线推进的一个重要监管里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638545418","title":"Verastem Oncology任命Michael P. Bailey为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2638545418","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638545418?lang=zh_cn&edition=full","pubTime":"2026-05-26 23:17","pubTimestamp":1779808620,"startTime":"0","endTime":"0","summary":"专注于RAS/MAPK通路驱动型癌症的生物制药公司Verastem Oncology今日宣布，任命Michael P． Bailey为公司董事会成员。与此同时，Robert Gagnon于2026年5月21日任期届满后正式卸任。　　Bailey现任LG化学旗下AVEO Pharmaceuticals总裁兼首席执行官，并自2015年1月起担任该公司董事。　　Verastem Oncology近期财务表现稳健。随着公司推进LGSOC业务并在2026年下半年实现自给自足的目标，Bailey在肿瘤药物商业化和产品全生命周期管理方面的深厚经验有望为董事会带来战略价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-26/doc-inhzfwqk1335245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894151","title":"高德红绿灯倒计时宣布出海，将逐步覆盖全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894151","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636894151?lang=zh_cn&edition=full","pubTime":"2026-05-20 10:50","pubTimestamp":1779245400,"startTime":"0","endTime":"0","summary":"新浪科技讯 5月20日上午消息，高德红绿灯倒计时宣布出海，将在全球更多国家和地区逐步落地。　　红绿灯倒计时是阿里巴巴旗下高德于2022年5月推出的产品功能，基于AI技术，能够对路口信号灯变化进行实时模拟与计算。　　截至目前，高德红绿灯倒计时已在中国大陆及港澳台地区全面落地，覆盖红绿灯路口近50万个，有效提升了交通路口的通行效率与安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2026-05-20/doc-inhyphnp1715201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518220886","title":"Verastem, Inc.盘中异动 大幅上涨5.14%报7.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220886","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518220886?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:49","pubTimestamp":1741625371,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日00时49分，Verastem, Inc.股票出现异动，股价快速拉升5.14%。截至发稿，该股报7.36美元/股，成交量51.1809万股，换手率1.15%，振幅7.43%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004931abf344c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004931abf344c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513211811","title":"Verastem, Inc.盘中异动 股价大涨5.21%报5.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513211811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513211811?lang=zh_cn&edition=full","pubTime":"2025-02-22 03:23","pubTimestamp":1740165786,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时23分，Verastem, Inc.股票出现异动，股价急速拉升5.21%。截至发稿，该股报5.86美元/股，成交量28.4278万股，换手率0.64%，振幅4.94%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222032306abd7ea85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222032306abd7ea85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512231196","title":"Verastem, Inc.盘中异动 大幅下挫5.03%报5.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512231196","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512231196?lang=zh_cn&edition=full","pubTime":"2025-02-19 03:09","pubTimestamp":1739905785,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日03时09分，Verastem, Inc.股票出现波动，股价急速下挫5.03%。截至发稿，该股报5.67美元/股，成交量30.2897万股，换手率0.68%，振幅5.53%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.90%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219030945a24ae609&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219030945a24ae609&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510891292","title":"Verastem, Inc.盘中异动 下午盘大幅下挫5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510891292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510891292?lang=zh_cn&edition=full","pubTime":"2025-02-11 03:28","pubTimestamp":1739215689,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日03时28分，Verastem, Inc.股票出现波动，股价大幅下挫5.01%。Verastem, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。其相关个股中，Dominari Holdings Inc.、Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为3139.85%、1672.88%、1411.40%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Biodexa Pharmaceuticals Plc、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为99.86%、92.63%、87.80%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211032809a240deb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211032809a240deb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508993691","title":"B. Riley Securities：维持Verastem(VSTM.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508993691","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508993691?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:39","pubTimestamp":1738345141,"startTime":"0","endTime":"0","summary":"B. Riley Securities：维持Verastem(VSTM.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至9.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/01013947922571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506025203","title":"Verastem, Inc.盘中异动 早盘股价大跌5.07%报5.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506025203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506025203?lang=zh_cn&edition=full","pubTime":"2025-01-28 00:25","pubTimestamp":1737995148,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日00时25分，Verastem, Inc.股票出现异动，股价急速跳水5.07%。截至发稿，该股报5.62美元/股，成交量40.5328万股，换手率0.91%，振幅7.26%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280025489874c27b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280025489874c27b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505271147","title":"Verastem, Inc.盘中异动 股价大涨6.75%报5.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505271147","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505271147?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:36","pubTimestamp":1737470169,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时36分，Verastem, Inc.股票出现波动，股价大幅上涨6.75%。截至发稿，该股报5.69美元/股，成交量3.997万股，换手率0.09%，振幅3.56%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.95%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223609abb34811&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121223609abb34811&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503885623","title":"Verastem, Inc.盘中异动 大幅上涨5.93%报5.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503885623","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503885623?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:31","pubTimestamp":1736951519,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时31分，Verastem, Inc.股票出现波动，股价快速上涨5.93%。截至发稿，该股报5.34美元/股，成交量1.411万股，换手率0.03%，振幅0.89%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152232009604b3f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152232009604b3f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.verastem.com","stockEarnings":[{"period":"1week","weight":-0.029},{"period":"1month","weight":0.2103},{"period":"3month","weight":0.3917},{"period":"6month","weight":0.9182},{"period":"1year","weight":0.1495},{"period":"ytd","weight":0.215}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Verastem, Inc.于2010年8月4日注册成立为一家特拉华州公司。该公司是一家处于后期开发阶段的生物制药公司，正在进行注册定向试验，致力于为与癌症作斗争的患者推进新药。该公司的管道专注于抑制癌症中关键信号通路的新型抗癌剂，这些信号通路可促进癌细胞存活和肿瘤生长，特别是RAF/MEK抑制和FAK抑制。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.073347},{"month":2,"riseRate":0.4,"avgChangeRate":-0.007088},{"month":3,"riseRate":0.466667,"avgChangeRate":0.082917},{"month":4,"riseRate":0.466667,"avgChangeRate":-0.020958},{"month":5,"riseRate":0.466667,"avgChangeRate":0.064718},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.050164},{"month":7,"riseRate":0.466667,"avgChangeRate":0.103729},{"month":8,"riseRate":0.4,"avgChangeRate":0.029734},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.060045},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.08102},{"month":11,"riseRate":0.733333,"avgChangeRate":0.120582},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.064523}],"exchange":"NASDAQ","name":"Verastem","nameEN":"Verastem"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verastem(VSTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Verastem(VSTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Verastem,VSTM,Verastem股票,Verastem股票老虎,Verastem股票老虎国际,Verastem行情,Verastem股票行情,Verastem股价,Verastem股市,Verastem股票价格,Verastem股票交易,Verastem股票购买,Verastem股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verastem(VSTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Verastem(VSTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}